Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14).
FT3/FT4
deiodination
immunotherapy
progression
renal cell carcinoma
survival
tyrosine kinase inhibitors
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
10
2021
accepted:
03
11
2021
entrez:
13
12
2021
pubmed:
14
12
2021
medline:
14
12
2021
Statut:
epublish
Résumé
Thyroid hormone impairment, represented as an alteration in levels of thyroid hormones and a lower fT3/fT4 ratio, has been correlated with a worse prognosis for both cancer and non-cancer patients. The role of baseline thyroid function in patients with metastatic renal cell carcinoma (mRCC) however, has not been studied yet. We recorded clinical data, baseline biochemical results, and oncological outcomes from 10 Oncology Units in Italy. We stratified patients into three groups according to the fT3/fT4 ratio value and subsequently analyzed differences in progression-free survival (PFS) and overall survival (OS) in the three groups. We also performed univariate and multivariate analyses to find prognostic factors for PFS and OS. We analyzed 134 patients treated with systemic treatment for mRCC. Median PFS in the low, intermediate, and high fT3/fT4 ratio group were 7.5, 12.1, and 21.7 months respectively (p<0.001); median OS in the three groups were 36.5, 48.6, and 70.5 months respectively (p =0.006). The low fT3/fT4 ratio maintained its prognostic role at the multivariate analysis independently from IMDC and other well-established prognostic factors. The development of iatrogenic hypothyroidism was not associated with a better outcome. We found that baseline thyroid hormone impairment, represented by a low fT3/fT4 ratio, is a strong prognostic factor in patients treated for mRCC in first line setting and is independent of other parameters currently used in clinical practice.
Sections du résumé
BACKGROUND
BACKGROUND
Thyroid hormone impairment, represented as an alteration in levels of thyroid hormones and a lower fT3/fT4 ratio, has been correlated with a worse prognosis for both cancer and non-cancer patients. The role of baseline thyroid function in patients with metastatic renal cell carcinoma (mRCC) however, has not been studied yet.
MATERIALS AND METHODS
METHODS
We recorded clinical data, baseline biochemical results, and oncological outcomes from 10 Oncology Units in Italy. We stratified patients into three groups according to the fT3/fT4 ratio value and subsequently analyzed differences in progression-free survival (PFS) and overall survival (OS) in the three groups. We also performed univariate and multivariate analyses to find prognostic factors for PFS and OS.
RESULTS
RESULTS
We analyzed 134 patients treated with systemic treatment for mRCC. Median PFS in the low, intermediate, and high fT3/fT4 ratio group were 7.5, 12.1, and 21.7 months respectively (p<0.001); median OS in the three groups were 36.5, 48.6, and 70.5 months respectively (p =0.006). The low fT3/fT4 ratio maintained its prognostic role at the multivariate analysis independently from IMDC and other well-established prognostic factors. The development of iatrogenic hypothyroidism was not associated with a better outcome.
CONCLUSION
CONCLUSIONS
We found that baseline thyroid hormone impairment, represented by a low fT3/fT4 ratio, is a strong prognostic factor in patients treated for mRCC in first line setting and is independent of other parameters currently used in clinical practice.
Identifiants
pubmed: 34900742
doi: 10.3389/fonc.2021.787835
pmc: PMC8655227
doi:
Types de publication
Journal Article
Langues
eng
Pagination
787835Informations de copyright
Copyright © 2021 Maruzzo, Verzoni, Vitale, Dionese, Buti, Galli, Zivi, Watutantrige-Fernando, Zielli, Zanardi, Sabbatini, Basso, Zagonel and Procopio.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Gerontol A Biol Sci Med Sci. 2013 Sep;68(9):1122-8
pubmed: 23459207
Adv Exp Med Biol. 2017;1026:233-249
pubmed: 29282687
Br J Haematol. 2017 Apr;177(1):95-105
pubmed: 28146267
Horm Cancer. 2014 Aug;5(4):240-6
pubmed: 24832769
J Clin Endocrinol Metab. 2018 May 1;103(5):1867-1876
pubmed: 29546287
J Clin Oncol. 1999 Aug;17(8):2530-40
pubmed: 10561319
Med Oncol. 2017 Apr;34(4):68
pubmed: 28343336
Front Cell Dev Biol. 2021 Jan 21;8:614030
pubmed: 33553149
Mediators Inflamm. 2016;2016:6757154
pubmed: 27051079
World J Nephrol. 2015 Jul 6;4(3):415-22
pubmed: 26167466
Clin Colorectal Cancer. 2018 Sep;17(3):e601-e615
pubmed: 30149875
Lancet Oncol. 2013 Feb;14(2):141-8
pubmed: 23312463
J Endocrinol. 2010 Apr;205(1):1-13
pubmed: 20016054
N Engl J Med. 2017 Jan 26;376(4):354-366
pubmed: 28121507
Ann Oncol. 2019 May 1;30(5):706-720
pubmed: 30788497
Future Oncol. 2016 Apr;12(7):909-19
pubmed: 26883094
PLoS One. 2017 Aug 3;12(8):e0181878
pubmed: 28771610
Expert Opin Ther Targets. 2013 Nov;17(11):1369-79
pubmed: 23991650
Eur J Cancer. 2020 Jul;133:66-73
pubmed: 32446145
Endocr Pract. 2008 Dec;14(9):1180-7
pubmed: 19158057